Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SNBP Sun BioPharma (SNBP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Sun BioPharma Stock (NASDAQ:SNBP) 30 days 90 days 365 days Advanced Chart Ad DTIWhy buying gold might be a mistakeSomething strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.If you're interested, check out the recording here while the link's still up. Get Sun BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$3.45▼$4.5052-Week Range N/AVolume49,422 shsAverage Volume26,926 shsMarket Capitalization$3.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.Read More… Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.If you're interested, check out the recording here while the link's still up. Receive SNBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sun BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SNBP Stock News HeadlinesSun Pharma share price plunges 5% after US ruling on Leqselvi launch - Here's what JPMorgan, UBS sayNovember 5, 2024 | msn.comSun Pharma shares in focus as US court blocks Leqselvi launchNovember 4, 2024 | msn.com“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…November 13, 2024 | Colonial Metals (Ad)Sun Pharma shares in spotlight after Q2 profit rises 28% YoY to Rs 3,040 crore. Should you invest?October 29, 2024 | msn.comIndia's Sun Pharma beats Q2 profit view on higher demand for specialty drugsOctober 28, 2024 | msn.comSun Pharma Q2 Results Preview: PAT may rise 25% YoY; healthy revenue growth seenOctober 27, 2024 | msn.comSun Pharmaceutical Industries falls Tuesday, still outperforms marketOctober 22, 2024 | marketwatch.comSun Pharmaceutical Industries rises Monday, still underperforms marketOctober 15, 2024 | marketwatch.comSee More Headlines SNBP Stock Analysis - Frequently Asked Questions How were Sun BioPharma's earnings last quarter? Sun BioPharma, Inc. (NASDAQ:SNBP) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. What other stocks do shareholders of Sun BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sun BioPharma investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Processa Pharmaceuticals (PCSA), Akero Therapeutics (AKRO), Athabasca Oil (ATH), Black Iron (BKI) and Berry (BRY). Company Calendar Last Earnings11/12/2020Today11/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SNBP CUSIPN/A CIKN/A Webwww.sunbiopharma.com Phone952-479-1196FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares9,649,000Free FloatN/AMarket Cap$3.96 million OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:SNBP) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sun BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sun BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
